ICD10 code of Li-Fraumeni syndrome and ICD9 code

Li-Fraumeni syndrome is identified by the ICD-10 code D48.9 (neoplasm of uncertain behavior, unspecified) or more specifically through Z80.0 (family history of malignant neoplasm of digestive organs) or Z84.81 (family history of carrier of genetic disease), as there is no single, unique ICD-10 code dedicated exclusively to this condition. In the older ICD-9 system, it was typically coded under 239.9 (neoplasm of unspecified nature) or V16.3 (family history of malignant neoplasm), reflecting the clinical challenge of coding a complex multi-system cancer predisposition syndrome.

What is the clinical significance of coding for Li-Fraumeni syndrome?

Because Li-Fraumeni syndrome is a complex genetic condition characterized by a significantly increased risk of developing various types of cancer, it does not have a single, disease-specific diagnostic code. In clinical practice, physicians often use a combination of codes to capture both the patient's genetic status and their specific cancer history. Li-Fraumeni syndrome is caused by a germline mutation in the TP53 tumor suppressor gene, which leads to a lifelong predisposition to malignancies such as soft tissue sarcomas, osteosarcomas, breast cancer, brain tumors, and adrenocortical carcinomas. Accurate coding is essential for facilitating insurance authorization for intensive cancer surveillance protocols, which are a cornerstone of managing Li-Fraumeni syndrome.

How is Li-Fraumeni syndrome diagnosed?

Diagnosis of Li-Fraumeni syndrome is typically confirmed through genetic testing to identify a pathogenic variant in the TP53 gene. Clinical criteria, such as the classic Chompret criteria, are often used to determine which patients should undergo genetic counseling and testing. These criteria include:

• A proband with a tumor belonging to the Li-Fraumeni syndrome tumor spectrum (e.g., soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumor, adrenocortical carcinoma, leukemia, or lung bronchoalveolar cancer) before age 46.


• At least one first- or second-degree relative with a Li-Fraumeni syndrome-related tumor (except breast cancer if the proband has breast cancer) before age 56.


• A proband with multiple tumors, including at least two Li-Fraumeni syndrome-related tumors.

Is Li-Fraumeni syndrome hereditary?

Yes, Li-Fraumeni syndrome is an autosomal dominant condition, meaning that an individual with a TP53 mutation has a 50% chance of passing the mutation to each of their children. While most cases are inherited, approximately 7% to 20% of cases arise from a de novo mutation, occurring for the first time in the affected individual. The DiseaseMaps.org community currently supports 53 people navigating the complexities of Li-Fraumeni syndrome, providing a space to share experiences regarding genetic testing and the lifelong emotional impact of this diagnosis.

Next steps

• Consult with a board-certified clinical geneticist to discuss TP53 testing and cascade testing for family members.


• Establish a relationship with a high-risk oncology surveillance clinic that specializes in early cancer detection for Li-Fraumeni syndrome.


• Connect with the DiseaseMaps.org community to share experiences and find support from others living with this rare condition.


• Maintain a detailed medical record of all screenings and personal/family cancer history to ensure accurate coding and insurance coverage for necessary preventive imaging.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Li-Fraumeni syndrome overview.


• Orphanet: Rare disease database entry for Li-Fraumeni syndrome (ORPHA:520).


• OMIM (Online Mendelian Inheritance in Man): #151623 Li-Fraumeni syndrome.


• National Cancer Institute (NCI): Li-Fraumeni Syndrome Genetics and Surveillance Guidelines.